Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach
Various mutations have accumulated since the first genome sequence of SARS-CoV2 in 2020. Mutants of the virus carrying the D614G and P681R mutations in the spike protein are increasingly becoming dominant all over the world. The two mutations increase the viral infectivity and severity of the diseas...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/11/1715 |
| _version_ | 1797467581675732992 |
|---|---|
| author | Mohamed G. Seadawy Abdel Rahman N. Zekri Aya A. Saeed Emmanuel James San Amr M. Ageez |
| author_facet | Mohamed G. Seadawy Abdel Rahman N. Zekri Aya A. Saeed Emmanuel James San Amr M. Ageez |
| author_sort | Mohamed G. Seadawy |
| collection | DOAJ |
| description | Various mutations have accumulated since the first genome sequence of SARS-CoV2 in 2020. Mutants of the virus carrying the D614G and P681R mutations in the spike protein are increasingly becoming dominant all over the world. The two mutations increase the viral infectivity and severity of the disease. This report describes an in silico design of SARS-CoV-2 multi-epitope carrying the spike D614G and P681R mutations. The designed vaccine harbors the D614G mutation that increases viral infectivity, fitness, and the P681R mutation that enhances the cleavage of S to S1 and S2 subunits. The designed multi-epitope vaccine showed an antigenic property with a value of 0.67 and the immunogenicity of the predicted vaccine was calculated and yielded 3.4. The vaccine construct is predicted to be non-allergenic, thermostable and has hydrophilic nature. The combination of the selected CTL and HTL epitopes in the vaccine resulted in 96.85% population coverage globally. Stable interactions of the vaccine with Toll-Like Receptor 4 were tested by docking studies. The multi-epitope vaccine can be a good candidate against highly infecting SARS-CoV-2 variants. |
| first_indexed | 2024-03-09T18:55:41Z |
| format | Article |
| id | doaj.art-589ecbcc1f9544b6b0406324c08764d1 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T18:55:41Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-589ecbcc1f9544b6b0406324c08764d12023-11-24T05:29:47ZengMDPI AGLife2075-17292022-10-011211171510.3390/life12111715Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico ApproachMohamed G. Seadawy0Abdel Rahman N. Zekri1Aya A. Saeed2Emmanuel James San3Amr M. Ageez4Biological Prevention Department, Chemical Warfare, 4.5 km Suez-Cairo Rd, Almaza, Cairo 11351, EgyptNational Cancer Institute, Cairo University, Giza 12613, EgyptNational Cancer Institute, Cairo University, Giza 12613, EgyptKwaZulu-Natal Research Innovation and Sequencing Platform, School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban 4001, South AfricaFaculty of Biotechnology, MSA University, 6 October City 12451, EgyptVarious mutations have accumulated since the first genome sequence of SARS-CoV2 in 2020. Mutants of the virus carrying the D614G and P681R mutations in the spike protein are increasingly becoming dominant all over the world. The two mutations increase the viral infectivity and severity of the disease. This report describes an in silico design of SARS-CoV-2 multi-epitope carrying the spike D614G and P681R mutations. The designed vaccine harbors the D614G mutation that increases viral infectivity, fitness, and the P681R mutation that enhances the cleavage of S to S1 and S2 subunits. The designed multi-epitope vaccine showed an antigenic property with a value of 0.67 and the immunogenicity of the predicted vaccine was calculated and yielded 3.4. The vaccine construct is predicted to be non-allergenic, thermostable and has hydrophilic nature. The combination of the selected CTL and HTL epitopes in the vaccine resulted in 96.85% population coverage globally. Stable interactions of the vaccine with Toll-Like Receptor 4 were tested by docking studies. The multi-epitope vaccine can be a good candidate against highly infecting SARS-CoV-2 variants.https://www.mdpi.com/2075-1729/12/11/1715COVID-19D614G mutationP681R mutationsepitope predictionin silico vaccine design |
| spellingShingle | Mohamed G. Seadawy Abdel Rahman N. Zekri Aya A. Saeed Emmanuel James San Amr M. Ageez Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach Life COVID-19 D614G mutation P681R mutations epitope prediction in silico vaccine design |
| title | Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach |
| title_full | Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach |
| title_fullStr | Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach |
| title_full_unstemmed | Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach |
| title_short | Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach |
| title_sort | candidate multi epitope vaccine against corona b 1 617 lineage in silico approach |
| topic | COVID-19 D614G mutation P681R mutations epitope prediction in silico vaccine design |
| url | https://www.mdpi.com/2075-1729/12/11/1715 |
| work_keys_str_mv | AT mohamedgseadawy candidatemultiepitopevaccineagainstcoronab1617lineageinsilicoapproach AT abdelrahmannzekri candidatemultiepitopevaccineagainstcoronab1617lineageinsilicoapproach AT ayaasaeed candidatemultiepitopevaccineagainstcoronab1617lineageinsilicoapproach AT emmanueljamessan candidatemultiepitopevaccineagainstcoronab1617lineageinsilicoapproach AT amrmageez candidatemultiepitopevaccineagainstcoronab1617lineageinsilicoapproach |